FLSC

10.0950.05%

Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) Stock Short Interest Report for October

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC - Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 17,259 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily volume of 112,857 shares, the days-to-cover ratio is currently 0.2 days.

Insider Activity at Frazier Life Sciences Acquisition Corp. II

In related news, CEO Albert Cha purchased 300,000 shares of the business's stock in a transaction on Thursday, October 15th. The shares were acquired at an average price of $10.00 per share, for a total transaction of $3,000,000.00. Following the purchase, the chief executive officer owned 300,000 shares of the company's stock, valued at $3,000,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Frazier Life Sciences Acquisition Corp. II to a "hold" rating in a report on Saturday, October 24th.

Check Out Our Latest Stock Report on Frazier Life Sciences Acquisition Corp. II

Frazier Life Sciences Acquisition Corp. II Price Performance

FLSC traded down $0.04 during trading on Friday, reaching $10.17. 3,763 shares of the company's stock were exchanged, compared to its average volume of 141,373. Frazier Life Sciences Acquisition Corp. II has a 1 year low of $10.10 and a 1 year high of $10.63.

About Frazier Life Sciences Acquisition Corp. II

(Get Free Report)

Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company, or SPAC, focused on identifying and combining with a business in the life sciences sector. The company does not operate a conventional commercial business and was formed to pursue a merger, acquisition, or similar business combination.

Its target opportunities may include companies involved in biotechnology, pharmaceuticals, medical devices, diagnostics, or other healthcare-related technologies. The company's objective is to provide a publicly traded platform for a private life sciences business through a business combination.

Frazier Life Sciences Acquisition Corp.

Further Reading

  • Five stocks we like better than Frazier Life Sciences Acquisition Corp. II
  • Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
  • 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
  • Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
  • Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Frazier Life Sciences Acquisition Corp. II Right Now?

Before you consider Frazier Life Sciences Acquisition Corp. II, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Frazier Life Sciences Acquisition Corp. II wasn't on the list.

While Frazier Life Sciences Acquisition Corp. II currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) Stock Short Interest Report for October

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source

Source: Market Beat The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.